Hlbpep

HLB PEP CO., LTD. is a South Korean peptide company that develops and manufactures peptide materials for pharmaceutical, bio and cosmetic applications and pursues peptide-based new drug candidates. Its product and service lines span catalog research peptides with known physiological activity (hormones, neuropeptides, antibiotic peptides and neurotoxins, with a stated focus on GPCR ligands and peptide neurotoxins), custom peptide synthesis, generic peptide APIs, and GMP peptide manufacturing services. Custom synthesis covers long-chain peptides, modified peptides and bulk-scale peptides, with in-house purification, lyophilization, quality testing and data management, and a published price list for normal peptides by purity tier (85-95%, >95%, >98%) and quantity (5-20 mg). A wide range of modifications is offered, including N-terminal acetylation and biotinylation, fluorescent dye labeling (FITC, FAM, TAMRA, Cy3, Cy5), phosphorylation, amidation and esterification, disulfide bonds, D-form and unusual amino acids, and fatty-acid or palmitic-acid conjugation. Analytical services include MALDI-TOF mass spectrometry and high-performance liquid chromatography.

The company states that its GMP plant was completed after roughly three years of preparation and construction and describes it as Korea's first plant dedicated to producing peptide pharmaceutical raw materials, equipped with facilities for synthesis, purification, drying and quality control of peptide APIs. HLB PEP also markets LABSENN, a premium peptide cosmetics brand developed in-house. Its stated R&D objective is continuous discovery of new drug candidates for technology transfer and commercialization, and press coverage describes a pipeline that includes peptides for diabetes and obesity treatment alongside a peptide pharmaceutical CDMO business.

HLB PEP is identified as an affiliate of HLB Group, a Korean pharmaceutical and bio conglomerate whose group listing describes HLB펩 (HLB Pep) as covering pharmaceutical, bio and cosmetic peptide materials and peptide drug development. The company is traded under the ticker 196300.KQ and is led by CEO Shim Kyung-jae.

Business model

The company sells peptide products and services: catalog research peptides, custom-synthesized peptides priced by residue count, purity and quantity, generic peptide APIs produced at its GMP facility, and GMP contract manufacturing/CDMO services for peptide pharmaceutical raw materials. It also operates a peptide cosmetics brand (LABSENN) and intends to monetize internally discovered drug candidates through technology transfer and commercialization. Orders and quotations are handled online through its website.

Revenue derives from product sales (catalog and custom peptides, generic peptide APIs, cosmetic peptide materials) and from contract development and manufacturing services, with additional planned income from licensing out new drug candidates.

Traction

The company reports a completed GMP peptide API plant and commercial catalog, custom, generic and GMP service lines, and in May 2026 signed an MOU with Japan's PeptiGrowth covering next-generation synthetic peptide growth factors and cytokines, advanced peptide manufacturing processes, GMP-based production systems and global supply expansion. In January 2026 it was reported to be working with Raymed on peptide-plus-AI radiopharmaceutical anticancer development.

Latest developments

Company notices list a January 2026 report on joint development of a peptide-plus-AI radioactive anticancer agent with Raymed, a September 2025 disclosure regarding an administrative disposition by the Gwangju Regional Office of the Ministry of Food and Drug Safety, and an HLB Group IR Day scheduled for April 2026. In May 2026 the company announced an MOU with PeptiGrowth of Japan to develop and manufacture advanced functional peptides for cell culture, regenerative medicine and cell therapy applications.